AI Article Synopsis

  • Sentinel lymph node status is important for predicting outcomes in cutaneous melanoma but poses logistical challenges and risks; thus, researchers aimed to find additional survival indicators.
  • This study evaluated 189 high-risk melanoma patients, focusing on established biomarkers (Ki67, p16, CD163) and clinical factors to create a prognostic score for survival.
  • The resulting score effectively predicted melanoma mortality risk, especially in sentinel node-negative patients, suggesting that combining clinical and biological markers could replace or supplement sentinel node biopsy when necessary.

Article Abstract

Sentinel lymph node status is a major prognostic marker in locally invasive cutaneous melanoma. However, this procedure is not always feasible, requires advanced logistics and carries rare but significant morbidity. Previous studies have linked markers of tumour biology to patient survival. In this study, we aimed to combine the predictive value of established biomarkers in addition to clinical parameters as indicators of survival in addition to or instead of sentinel node biopsy in a cohort of high-risk melanoma patients. Patients with locally invasive melanomas undergoing sentinel lymph node biopsy were ascertained and prospectively followed. Information on mortality was validated through the National Death Index. Immunohistochemistry was used to analyse proteins previously reported to be associated with melanoma survival, namely Ki67, p16 and CD163. Evaluation and multivariate analyses according to REMARK criteria were used to generate models to predict disease-free and melanoma-specific survival. A total of 189 patients with available archival material of their primary tumour were analysed. Our study sample was representative of the entire cohort (N = 559). Average Breslow thickness was 2.5 mm. Thirty-two (17%) patients in the study sample died from melanoma during the follow-up period. A prognostic score was developed and was strongly predictive of survival, independent of sentinel node status. The score allowed classification of risk of melanoma death in sentinel node-negative patients. Combining clinicopathological factors and established biomarkers allows prediction of outcome in locally invasive melanoma and might be implemented in addition to or in cases when sentinel node biopsy cannot be performed.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.30085DOI Listing

Publication Analysis

Top Keywords

sentinel node
16
locally invasive
16
node status
12
node biopsy
12
invasive melanoma
8
sentinel lymph
8
lymph node
8
established biomarkers
8
study sample
8
sentinel
7

Similar Publications

A unique collaboration of multi-disciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to two-centimeter safety margins. For a correct stage classification and treatment decision, a sentinel lymph node biopsy shall be offered in patients with tumor thickness ≥ 1.

View Article and Find Full Text PDF

Prognostic significance of lymph node metastasis of soft tissue sarcoma of the extremities. National cancer institute experience.

Int J Clin Oncol

December 2024

Department of Surgical Oncology, National Cancer Institute, Cairo University, Kasr Al Eini St., Fom El Khalig Sq., P.C. 11796, Cairo, Egypt.

Background And Objective: Lymph node metastasis (LNM) in soft tissue sarcoma (STS) of the extremities is relatively rare. We aimed to evaluate the prognosis and the survival of patients with LNM and correlate them to the pattern of metastasis.

Methods: A retrospective study of patients diagnosed with STS of the extremities from 2015 to 2019.

View Article and Find Full Text PDF

Methemoglobinemia is a rare but potentially life-threatening condition in which hemoglobin is oxidized, impairing the oxygen-carrying capacity. While congenital forms exist, acquired methemoglobinemia can occur in perioperative settings, especially following exposure to oxidizing agents such as dyes used in sentinel lymph node biopsy (SLNB). Patent Blue V, a synthetic aniline dye commonly used for SLNB, has been associated with rare but serious adverse effects, including methemoglobinemia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!